Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price rose 8.1% during mid-day trading on Monday . The company traded as high as $3.77 and last traded at $3.75, with a volume of 87,079 shares trading hands. The stock had previously closed at $3.47.

ABEO has been the subject of a number of analyst reports. Rodman & Renshaw reissued a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, April 20th. Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Wednesday, April 27th. Maxim Group reissued a “buy” rating and set a $6.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, May 17th. Finally, FBR & Co reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Sunday, May 22nd.

The stock’s market capitalization is $123.97 million. The company’s 50 day moving average price is $2.66 and its 200-day moving average price is $2.67.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.04. Equities analysts forecast that Abeona Therapeutics Inc. will post ($0.66) EPS for the current fiscal year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC increased its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.